Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment

Molecular Cancer

Review

Hong Zhe¹  Yan-Yang Wang¹  Ren Zhao¹ 

[1] Department of Radiation Oncology, General Hospital of Ningxia Medical University, No.804 Shengli Str, Yinchuan, Ningxia, China;

关键词: Triterpenoid;    CDDO-Me;    Solid cancer;    Prevention;    Treatment;    Mechanisms;   

DOI  :  10.1186/1476-4598-13-30

 received in 2013-09-07, accepted in 2014-02-12,  发布年份 2014

来源: Springer

【 摘 要 】

Solid cancer remains a major cause of death in the world. As limited treatment options are currently available to patients with solid cancer, novel preventive control and effective therapeutic approaches are considered to be reasonable and decisive measures to combat this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, poses various pharmacological properties. A large number of triterpenoids exhibit cytotoxicity against a variety of cancer cells, and cancer preventive, as well as anticancer efficacy in preclinical animal models. To improve antitumor activity, some synthetic triterpenoid derivatives have been synthesized, including cyano-3,12-dioxooleana-1,9(11)- dien-28-oic (CDDO), its methyl ester (CDDO-Me), and imidazolide (CDDO-Im) derivatives. In this review, we will critically examine the current preclinical evidences of cancer preventive and therapeutic activity about one of the synthetic triterpenoids, CDDO-Me. Both in vitro and in vivo effects of this agent and related molecular mechanisms are presented.

【 授权许可】

CC BY   
© Wang et al.; licensee BioMed Central Ltd. 2014